The Buda Health Center is one of the leading private institutions of Budapest offering its patients personalized comprehensive health care.


Sipos, László, MD Ph.D.


I graduated from the Faculty of Medicine of Semmelweis Medical University in 1985. After completing my studies, I was an intern at the 1st Department of Pathology and Experimental Cancer Research of Semmelweis Medical University, where I also participated in the education of dental students as a lecturer and practical course instructor.

Medical specialism

  • Neurosurgery
    • Surgery of brain and skull base tumors

    • Neuro-oncology

    • Radiosurgical treatment of brain tumors diagnosed jointly with the National Institute of Oncology (cranial surgery without opening the skull)

    • Chemotherapy of brain tumors

    • Vascular neurosurgery
  • Spinal surgery

Professional experience

  • 1986 – 2008, 2013 – : National Institute of Neurosurgery
    • 2003 – 2008, 2013 – : Chief physician
    • 2005 – 2008: Chief physician, head of department
    • 2013 – : Department of Skull Base Surgery and Vascular Neurosurgery
      • Chief physician, head of department
  • 1987: Department of Neurosurgery, Universitätsklinikum Erlangen
  • 1989: Department of Neurosurgery, Vancouver General Hospital
  • 1992 – 1993: Wessex Neurological Centre, Southampton General Hospital
    • Visiting Senior Registrar
  • 1995: Department of Neurosurgery, University Hospital of Wales
  • 2008 – 2013: Gemeinschaftspraxis und Op-Zentrum
    • Niedergelassener Neurochirurg
  • 2008 – 2011: Köln and Düsseldorf
    • Neurosurgery consultant
  • 2013 – : Department of Neurosurgery, Semmelweis University
    • Associate professor
  • 2020 – : Buda Health Center

Education and qualifications

  • 1985: Faculty of Medicine, Semmelweis University
  • 1991: qualifying exam in neurosurgery
  • 1992: The European Association of Neurosurgical Societies continuing education training course, neurosurgical training course
  • 1997: “Studies in Hospital Financing and Mid-Level Hospital Management” course, Faculty of Postgraduate Medical Education, Haynal Imre University of Health Sciences
  • 2014: qualifying exam in clinical oncology

Language skills

  • English, intermediate level
  • German, intermediate level
  • Italian, intermediate level

Professional and society membership

  • 1991 – : Brain Tumor Group, European Organization for Research and Treatment of Cancer (EORTC)
  • 2000 – 2012: Hungarian Society of Neuro-oncology
    • Founding member
    • 2000: Secretary
    • 2000 – 2012: Member of the board
    • 2003 – 2008: Chairman
  • Hungarian Neurosurgical Society
    • 2010 – 2014: Member of the board
  • The European Association of Neurosurgical Societies
  • European Association of Neuro-oncology
  • German Medical Association
  • Scientific Committee on Surgery, Department of Medical Sciences, Hungarian Academy of Sciences

Scientific activity

  • 1994 – : Radiosurgery Working Group, National Institute of Oncology
  • 1995 – : National Institute of Neurosurgery
    • Training of medical students and resident physicians

    • Lecturer at continuing education training courses for neurosurgery, neurology, oncology, and radiotherapy specialists

    • 1st Department of Anatomy and Department of Neurology, Semmelweis University
  • Neurosurgery practical training in English
    • Department of Neurosurgery, Semmelweis University
  • Neurosurgery practical training in German
  • In 1998, our article titled "The role and importance of CT-guided stereotactic brain biopsy in neurosurgery” published in Orvosi Hetilap (“Medical Weekly”) was awarded the Markusovszky Lajos Prize.
  • In 1999, I have successfully defended my PhD thesis titled “Specific clinical and immunologic examination of adult-onset suprentorial gliomas”. 
  • In collaboration with the Oncoradiology and Radiotherapy Center of Uzsoki Street Hospital (chief physician Csaba Nemeskéri, MD), we were the first in the country to use high-dose-rate interstitial brachytherapy for the treatment of intracranial tumors. 
  • The body of my scientific work is marked by 35 scientific publications in English and Hungarian, 8 book chapters and participation in 47 international and Hungarian congresses.,
  • Congresses
    • 14th International Cancer Congress, Budapest, August 21-27, 1986.

    • International Symposium on Advances in Neuro-oncology, Sanremo, September 26-29, 1990.

    • 8th International Symposium on Intracranial Pressure, Rotterdam, June 16-20, 1991.

    • 9th European Congress of Neurosurgery, Moscow, June 23-28, 1991.

    • International Conference and Course on Stereotactic Radiotherapy/Radiosurgery, Amsterdam, May 6-8, 1993.

    • 9th International Symposium on Intracranial Pressure, Nagoya, May 16-19, 1994.

    • 12th International Congress on Stereotactic and Functional Neurosurgery, Milan, June 12-15, 1996.

    • 2nd Congress of the European Association for Neuro-oncology, Würzburg, October 6-9, 1996.

    • 9th International Brachytherapy Conference, Boston, MA, April 23-29, 1997.

    • 3rd Congress of the European Association for Neuro-oncology,Versailles, September 13-16, 1998.

    • Magyar Idegsebészeti Társaság XV. Kongresszusa, Miskolc, május 11-13, 2000.

    • EORTC Brain Tumor Group Business Group Meeting, Brussels, November 4, 2000.

    • 12th World Congress of Neurosurgery, Sydney, September 16-20, 2001.

    • 5th Congress of the European Association for Neuro-oncology, Florence, September 7-10, 2002.

    • 2nd International Conference in Neuro-oncology: Future Trends in the Treatment of Brain Tumours. Padua, 14-15 March, 2003.

    • 12th European Congress of Neurosurgery, Lisboa, 7-12 September, 2003.

    • Magyar Idegsebészeti Társaság XVI. Kongresszusa, Székesfehérvár, November 7-8, 2003.

    • 6th Congress of the European Association for Neuro-oncology-2nd Meeting of the World Federation of Neuro-oncology, Edinburgh, 5-8 May, 2005.

    • Neuroonkológia Tudományos Fórum, Budapest, május 20, 2005.

    • 13th World Congress of Neurosurgery, Marrakesh, 19-24 June, 2005.

    • Magyar Onkológusok Gyógyszerterápiás Tudományos Társaságának 3. Kongresszusa, Budapest, március 16-18, 2006.

    • 2nd Perspective in Central Nervous System Malignancies, Budapest, 7-8 April, 2006.

    • Neuroonkológia Tudományos Fórum, Budapest, május 19, 2006.

    • 7th Congress of the European Association for Neuro-oncology, Wien, 14-17 September, 2006.

    • 4th Central European Neurosurgical Society, Budapest, október 13-15, 2006.

    • Tudományos fórum a Magyar Neuro-Onkológiai Társaság és a Magyar Onkológusok Társasága rendezésében, Eger, november 24-25 2006.

    • Magyar Neuro-onkológiai Társaság VIII. Tudományos Ülése Balatonfüred, október 5-6 2007.

    • National Conference of Neurooncology, Kolozsvár, 22-24 November, 2007.

    • 8th Congress of the European Association for Neuro-oncology, Barcelona, 12-14 September, 2008.

    • Magyar Neuro-onkológiai Társaság IX. Tudományos Ülése, Balatonfüred, Hotel Silver október 3-4 2008.

    • Magyar Neuro-onkológiai Társaság X. Kongresszusa, Debrecen, október 1-3, 2009.

    • Magyar Neuro-onkológiai Társaság ülése, Visegrád, május 27-29, 2010.

    • 9th Congress of the European Association for Neuro-oncology, Maastricht, 16-19 September, 2010.

    • Magyar Neuro-onkológiai Társaság XI. Kongresszusa, Debrecen, október 29-30, 2010.

    • Controversies and Evidence in Neurosurgery, St. Anton, Österreich, március 24-27, 2011.

    • Magyar Idegsebészeti Tásaság 2011. évi Nemzeti Kongresszusa, Szeged, október 20-22 , 2011,

    • Magyar Szenológiai Társaság Tudományos Fóruma, Kecskemét, május 23-24, 2014,

    • Updated oncology 2014: State of the art News & challenging topics. Bucharest, június 16-20, 2014,

    • Magyar Idegsebészeti Tásaság 2014. évi Nemzeti Kongresszusa, Budapest, november 20-22 , 2014,

    • Magyar Stroke Társaság XII Konferenciája, Sopron, szeptember 17-19, 2015,

    • Magyar Onkológusok XXXI. Kongresszusa, Budapest, november 19-21, 2015,

    • Magyar Szenológiai Társaság Tudományos Fóruma, Mátraháza, április 15-16, 2016,

    • 10th FENSForum of Neuroscience, Copenhagen, 2-6 July, 2016,

    • 12th Congress of the European Association for Neuro-oncology, Mannheim/Heidelberg, 12-16 October, 2016,

    • MKOT Update '17, Balatonfüred, június 16-17, 2017,

    • Magyar Onkológusok Társaságának XXXII - MaNOT közös Kongresszusa, Debrecen, november 16-18, 2017,

    • MKOT Update '18, Mátraháza, június 15-16, 2018,

    • AcroAkadémia, Pfizer, Zamárdi, szeptember 7-8, 2018,

    • 27th Congress of The Hungarian Society of Neuroradiology, november 7-9, 2019.
  • Publications
    • 1./ Szende B, Lapis K, Pál K, Sipos L, Dénes L, Kisfaludy L.: The effect of TP-3 (Arg-Lys-Asp), TP4 (Arg-Lys-Asp-Val) and TP5 on the metastatic capacity of intravenously injected Lewis lung tumor cells. Immunopharmacology and immunotoxicology 9:19-24, 1987

    • 2./ Sipos L, Áfra D.: A monoclonalis antitestek alkalmazásának lehetôségei a malignus glioma diagnosztikájában és kezelésében. Ideggy Szle 42: 435-441, 1989

    • 3./ Wakabayashi T, Yoshida J, Sipos L, Szeifert Gy, Fazekas I, Slowik F, Benczur M, Áfra D, Pásztor E.: Monoclonal antibody OITIC3-11 as an
      immunohistochemical probe for the identification of glial and proliferating cells. Neuroimmunological Res 11(30):209-213, 1989

    • 4./ Major O, Czirják S, Horváth M, Sipos L: Spontaneous spinal epidural haematomas. Acta Neurochir 111:40-42, 1991

    • 5./ Sipos L, Major O, Áfra D.: Chronic epidural haematomas. Report of 33 cases. Zbl Neurochir 53:74-77, 1992

    • 6./ Sipos L, Wakabayashi T, Fazekas I, Szeifert GT, Áfra D.: Characterisation of human gliomas by a monoclonal antibody both on tissue culture and paraffin-embedded sections. Neurological Res 14: 263-266, 1992

    • 6./b Sipos L, Wakabayashi T, Szeifert Gy, Fazekas I, Áfra D: Humán gliomák vizsgálata az OITI C3-11 monoklonális antitesttel. Clin Neurosci/Ideggy Szemle 47; (1-2): 36-39, 1994

    • 7./ Fedorcsák I, Sipos L, Horváth Á, Osztie É.: Effect of radiosurgery on malignant melanoma brain metastases.A long-term survival. J Neuro-Oncol 16:173-176, 1993

    • 8./ Szeifert GT, Sipos L, Horváth M, Sarker MH, Major O, Salomváry B, Czirják S, Bálint K, Slowik F, Kolonics L, Pásztor E.: Pathological characteristics of surgically removed craniopharyngiomas. Analysis of 131 cases. Acta Neurochir 124:139-143, 1993

    • 9./ Áfra D, Mayer Á, Sipos L.: Multimodality treatment of anaplastic supratentorial gliomas with high-dose Dibromodulcitol and Dibromodulcitol plus BCNU. Clin Neurosci/Ideggy Szle 46:420-424, 1993

    • 10./ Fedorcsák I, Horváth Á, Kontra G, Sipos L, Osztie É.: The effect of stereotactic linac based radiosurgery in the treatment of brain metastases. Acta Neurochir 122:161, 1993

    • 11./ Major O, Fedorcsák I, Sipos L, Hantos P, Kónya E, Dobronyi I, Paraicz E.: Slit-ventricle syndrome in shunt operated children. Acta Neurochir 127:69-72, 1994

    • 12./ Hildebrand J, Sahmoud T, Mignolet F, Brucher JM, Áfra D and EORTC Brain Tumour Group: Adjuvant therapy with Dibromodulcitol and BCNU increases survival of patients with malignant gliomas. Neurology 44:1479-1483, 1994

    • 13./ Nemeskéri Cs, Sipos L, Fedorcsák I, Tuzson Z, Mayer Á.: High dose rate afterloading interstitialis agyi brachytherápia. Magyar Radiológia 70: 83-86, 1996

    • 14./ Sipos L, Áfra D.: Felnőttkori malignus gliomák diagnosztikus és terápiás lehetőségei. Orvosi Hetilap, 137:2187-2191, 1996

    • 15./ Sipos L, Horváth Á, Osztie É, Fedorcsák I.: Stereotactic radiosurgery for brain metastases.Our results with a 9MeV linear accelerator adapted for radiosurgery. J Neuro-oncol, 30:157, 1996

    • 16./ Banczerowski P, Sipos L, Vajda J.: Aneurysm of the internal auditory artery: Our experience and review of the literature. Acta Neurochir 138:1157-1162, 1996

    • 17./ Sipos L, Vajda J.: Craniopharyngioma of the third ventricle. Acta Neurochir 139:92-93, 1997

    • 18./ Sipos L, Áfra D.: Re-operations of supratentorial anaplastic astrocytomas. Acta Neurochir 139:99-104, 1997

    • 19./ Fedorcsák I, Sipos L, Slowik F, Osztie É.: CT vezérelt stereotaxiás agyi biopszia jelentősége és szerepe az idegsebészetben. Tapasztalataink 523 eset kapcsán. (Our experiences with CT guided stereotactic biopsies in 523 intracranial lesions.) Orvosi Hetilap 139: 475-478, 1998.

    • 20./ Sipos L, Szegedi Zs, Fedorcsák I, Áfra D, Szende B: Apoptosis and p53 expression in human gliomas. Pathology Oncology Research 4:267-270, 1998.

    • 21./ Áfra D, Osztie É, Sipos L, Vitanovics D: Preoperative history and postoperative survival of supratentorial low-grade astrocytomas. British J Neurosurg 13:299-305, 1999.

    • 22./ Áfra D, Sipos L, Vitanovics D: A recidív supratentorialis malignus gliomák kemoterápiás kezelése. Clin Neurosci/Ideggy Szle 55:38-44, 2002.

    • 23./ Sipos L, Vitanovics D, Áfra D: Recidív malignus gliomák kezelése temozolomide-dal. Orvosi Hetilap, 143:1201-1204, 2002.

    • 24./ Vitanovics D, Sipos L, Áfra D: BCNU-DBD (Dibromodulcitol) chemotherpay of recurrent supratentorial anaplastic astrocytomas and glioblastomas. Neoplasma, 49:342-345, 2002.

    • 25./ Banczerowski P, Simó M, Sipos L, Slowik F, Benoist Gy, Veres R: Primary inramedullary glioblastoma of the spinal cord: report of eight cases. Clin Neurosci 56:28-32, 2003.

    • 26./ Fedorcsák I, Sipos L: Agyi melanoma áttétek kezelése. Magyar Onkológia 47:109-112, 2003.

    • 27./ van den Bent MJ, Delattre J-Y, Brandes AA, Xuan KH, Taphoorn MJB, Bernsen HJJA, Frenay M, Tijssen CC, Grisold W, Sipos L, Haaxma H, Kros JM, van Kouwenhoven M, Vecht ChJ, Allgeier A, Lacombe D, Gorlia T: Adjuvant PCV improves progression free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized EORTC phase III trial. J Clin Oncol, 24:2715-2722, 2006.

    • 28./ Sipos L: Felnőttkori intrakraniális daganatok diagnosztikájának rövid áttekintése. Háziorvos Továbbképző Szle, 773-776, 2006.

    • 29./ Banczerowski P, Bálint K, Sipos L: Temporal extradural ectopic craniopharyngeoma. J Neurosurg, 107:178-180, 2007.

    • 30./ Kouwenhoven MC, Gorlia T, Kros JM, Ibdaih A, Brandes AA, Bromberg JE, Mokhtari K, van Duinen SG, Teepen JL, Wesseling P, Vandenbos F, Grisold W, Sipos L, Mirimanoff R, Vecht CJ, Allgeier A, Lacombe D, van den Bent MJ: Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951. Neuro Oncol 11(6):737-46, 2009.

    • 31./ van Den Bent MJ, Hoang-Xuan K, Brandes AA, Kros JM, Kouwenhoven MC, Taphoorn MJ, Delattre J, Bernsen HJ, Frenay M, Tijssen, Grisold W, Sipos L, Enting RH, Dinjens WN, French P, Vecht CJ, Allgeier A, Lacombe DA, Gorlia T: Adjuvant PCV chemotherapy in newly diagnosed anaplastic oligodendroglioma – long term follow-up of EORTC Brain Tumor Group study 26951. Journal of Clinical Oncology 31:(3) pp. 344-350. 2013.

    • 32./ Lővey J, Fedorcsák I, Bajcsay A, Sipos L, Mangel L, Kásler, M, Bagó A: Glioblastoma multiforme posztoperatív radio-kemoterápiájának eredményei. Magyar Onkológia 57:232-239, 2013.

    • 33./ Misik F, Sipos L, Reiniger L, Czirják S: Intra-suprasellarisan elhelyezkedő hypophysis adenomát utánzó choroid plexus papilloma. Magyar Onkológia Szuppl 61:1, 66, 2017,

    • 34./ Czigléczki G, Sinkó D, Reiniger L, Fedrocsák I, Bagó A, Nemeskéri Cs, Sipos L: Bevacizumab terápia alkalmazása sotán nyert tapasztalataink agyi glioblastoma első progresszióját követően. Clin Neurosci/Ideggy Szle, 72(5-6), 2019,,

    • 35./ Sipos L, Bajcsay A, Kontra G, Czirják S, Jánváry L, Fedorcsák I, Polgár Cs: Korai tapasztalataink CyberKnife-kezeléssel suprasellarisan is terjedő hypernephroma áttét esetén. Clin Neurosci/Ideggy Szle 72(11–12) 427-431, 2019,

Should You like to make an appointment with our collegue for private consultation, please dial the number +36-1-489-5200, where our dispatchers will answer your call between 8am and 8pm every weekday!

Suspension of outpatient and inpatient care in non-acute cases

Dear Visitor,

Amidst the current epidemiological situation and in line with the orders of the competent government bodies, the Buda Health Center (BEK Kft.) is suspending its outpatient and inpatient care in non-acute cases with immediate effect.      

We will continuously keep our contractual partners posted about how the logistics of the services evolve through the competent experts and those responsible for organising our healthcare provision.      

As far as ongoing treatments are concerned, our dispatchers will continuously keep patients posted following the guidance of their respective doctors. Should you have any questions, we recommend contacting your doctor via email through the institute’s email address.      

This measure will change based on central orders upon the alleviation of the epidemic.      


Péter Pál Varga, M.D.
General Director